Diagnosis of the neglected tropical disease, Buruli ulcer, can be made by acid-fast smear microscopy, specimen culture on mycobacterial growth media, polymerase chain reaction (PCR), and/or histopathology. All have drawbacks, including non-specificity and requirements for prolonged culture at 32°C, relatively sophisticated laboratory facilities, and expertise, respectively. The causative organism, Mycobacterium ulcerans, produces a unique toxin, mycolactone A/B (ML) that can be detected by thin layer chromatography (TLC) or mass spectrometric analysis. Detection by the latter technique requires sophisticated facilities. TLC is relatively simple but can be complicated by the presence of other lipids in the specimen. A method using a boronate-assisted fluorogenic chemosensor in TLC can overcome this challenge by selectively detecting ML when visualized with UV light. This report describes modifications in the fluorescent TLC (F-TLC) procedure and its application to the mouse footpad model of M. ulcerans disease to determine the kinetics of mycolactone production and its correlation with footpad swelling and the number of colony forming units in the footpad. The response of all three parameters to treatment with the current standard regimen of rifampin (RIF) and streptomycin (STR) or a proposed oral regimen of RIF and clarithromycin (CLR) was also assessed. ML was detectable before the onset of footpad swelling when there were <105 CFU per footpad. Swelling occurred when there were >105 CFU per footpad. Mycolactone concentrations increased as swelling increased whereas CFU levels reached a plateau. Treatment with either RIF+STR or RIF+CLR resulted in comparable reductions of mycolactone, footpad swelling, and CFU burden. Storage in absolute ethanol appears critical to successful detection of ML in footpads and would be practical for storage of clinical samples. F-TLC may offer a new tool for confirmation of suspected clinical lesions and be more specific than smear microscopy, much faster than culture, and simpler than PCR.
The diagnosis of Buruli ulcer, caused by infection with Mycobacterium ulcerans, is complicated by its resemblance to other diseases that may also cause ulcers in the skin. Clinical diagnosis can be supported by microscopic detection of acid-fast bacilli in the skin, by prolonged culture of at least 8 weeks, in a dedicated incubator set at 32°C, or by the polymerase chain reaction in a well-equipped laboratory usually far from the clinic where the patient comes for treatment. The treatment involves taking two drugs, one requiring injections, every day for two months, a burden for patients and their families. Since all drugs may have side effects, it is important that the treatment be appropriate for the patient's disease. We describe a new technique to rapidly and inexpensively detect the presence of the unique toxin produced by M. ulcerans in the mouse footpad model of Buruli ulcer. We show that the toxin can be detected in footpads before the development of signs of the disease, that more toxin is produced as the disease progresses, and that toxin levels decline in mice treated with either the current standard regimen of rifampin and streptomycin or a proposed all-oral drug regimen of rifampin and clarithromycin.
Citation: Converse PJ, Xing Y, Kim KH, Tyagi S, Li S-Y, Almeida DV, et al. (2014) Accelerated Detection of Mycolactone Production and Response to Antibiotic Treatment in a Mouse Model of Mycobacterium ulcerans Disease. PLoS Negl Trop Dis 8(1): e2618. doi:10.1371/journal.pntd.0002618
Editor: Richard O. Phillips, Kwame Nkrumah University of Science and Technology (KNUST) School of Medical Sciences, Ghana
Received: September 19, 2013; Accepted: November 21, 2013; Published: January 2, 2014
Copyright: © 2014 Converse et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors are grateful for the funding of this work that was provided by NIH-NIAID (http://www.niaid.nih.gov) R01-AI.082612. YX, KHK, and YK gratefully acknowledge the Eisai USA Foundation for financial support to Harvard University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Buruli ulcer, a neglected tropical disease caused by Mycobacterium ulcerans, occurs in marshy environments in scattered countries and regions on most of the world's continents . While its mode of transmission remains uncertain, it is now known that the principal virulence factor is a secreted cytotoxic lipid, mycolactone , whose synthetic enzymes are encoded on a giant plasmid . Both features are unique among mycobacteria. Until nearly 10 years ago, the only accepted mode of treating the disease was to surgically remove the lesion and surrounding tissue followed by skin grafting . Using a mouse footpad model developed in the 1950s  and applying the lessons of tuberculosis and leprosy chemotherapy, combination regimens of antibiotics were tested in the early 2000s –. The most effective treatment was found to be a combination of rifampin (RIF), an oral drug used for treatment of most mycobacterial infections, and streptomycin (STR), an injectable drug originally used to treat tuberculosis. Subsequent clinical studies – supported the efficacy of this regimen and resulted in the replacement of surgery with antimicrobial treatment in most programs around the world .
Different forms of mycolactone are produced by M. ulcerans in different locales. They can be detected by mass spectrometry, cytotoxicity assays, or thin-layer chromatography (TLC) –. The major mycolactone is mycolactone A/B . Total synthesis of the mycolactones was demonstrated ,  and synthetic mycolactone A/B has been made available for research purposes. Seeking to improve the TLC method by reducing background spots, Spangenberg and Kishi  developed a boronate-assisted fluorescent-TLC (F-TLC) method in which there is a marked reduction of background spots. The TLC plate is developed by immersion in a boronic acid acetone solution that binds to mycolactone and fluoresces on excitation by ultraviolet light. Interestingly, this method is specific to detect human mycolactones, but not fish or frog mycolactones, as well as some unknown contaminants. Unpublished results indicated that synthetic mycolactone spiked into tissue could be detected by F-TLC but detection in clinical samples was often problematic, probably due to the storage method of samples. These results prompted further development and refinement of the F-TLC assay, which is reported here.
The mouse footpad model has the advantage of a readily visible and progressive swelling of the infected foot , –. Harvested footpads can also be processed for enumeration of M. ulcerans colony forming units (CFU) by culture on mycobacterial media for up to 12 weeks at 32°C. Previous studies documented histological and microbiological changes after infection as well as changes in toxin levels in frozen footpads before and after treatment with RIF+STR –. Among the goals of the World Health Organization Global Buruli Ulcer Initiative is to find an all-oral regimen, in other words to replace STR with an oral alternative such as clarithromycin (CLR) –.
In the current study, we documented weekly changes in footpad swelling, CFU counts, and toxin levels in infected mouse footpads before and after treatment, comparing the efficacy of RIF+STR and RIF+CLR. After preliminary studies with convenience samples, we were able to show that mycolactone may be best preserved not by freezing but by storage in absolute ethanol, a finding that could also be of practical benefit under field conditions.
Materials and Methods
M. ulcerans 1615 (Mu1615), an isolate originally obtained from a patient in Malaysia in the 1960s , was kindly provided by Dr. Pamela Small, University of Tennessee. According to Dr. Small (personal communication), this strain is a stable producer of mycolactone A/B whereas modern African strains often lose the capacity to produce mycolactone unless passaged in mice (Drs. Stewart Cole and Laurent Marsollier, personal communication to JHG). Previous studies have confirmed that this strain produces mycolactone A/B and kills macrophages and fibroblasts , , . The strain was passaged in mouse footpads before use in these studies. The bacilli were harvested from swollen footpads at the grade 2 level, i.e., swelling with inflammation of the footpad .
All animal procedures were conducted according to relevant national and international guidelines. The study was conducted adhering to the Johns Hopkins University guidelines for animal husbandry and was approved by the Johns Hopkins Animal Care and Use Committee, protocol MO11M240. The Johns Hopkins program is in compliance with the Animal Welfare Act regulations and Public Health Service (PHS) Policy and also maintains accreditation of its program by the private Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.
RIF and STR were purchased from Sigma (St. Louis, MO). CLR was kindly provided by Abbott (Abbott Park, IL). STR and RIF were dissolved in distilled water, and CLR was dissolved in distilled water with 0.05% agarose for administration to mice. All drugs were administered 5 days per week in 0.2 ml. RIF (10 mg/kg) and CLR (100 mg/kg) were administered by gavage. STR (150 mg/kg) was administered by subcutaneous injection.
Infection and CFU analysis
BALB/c mice, age 4–6 weeks (Charles River, Wilmington, MA), were inoculated in the right hind footpad with approximately 4.54 log10 (3.45×104) CFU of Mu1615 in 0.03 ml PBS. Footpads were harvested weekly from 8 mice (5 for CFU count, 3 for ML detection) at different time points after infection (Table 1) and before treatment, up to ≥grade 3 swelling. After the onset of grade 2 swelling (week 6), treatment with RIF+STR or CLR was administered for 5 weeks (week 11 after infection). Groups of treated mice were also sacrificed for these analyses. Footpad tissue was harvested, minced with fine scissors, suspended in 2.5 ml PBS, serially diluted, and plated on Middlebrook selective 7H11 plates (Becton-Dickinson, Sparks, MD). Plates were incubated at 32°C and colonies were counted after 10 weeks with a final determination at 12 weeks of incubation.
Analysis of mycolactone A/B
Footpads were harvested for detection of mycolactone by stripping bottom and top sides of the infected and contralateral footpads and then immediately immersing the two sides into a polypropylene Micrewtube® tube with O-ring and screw cap (Simport Scientific, Beloeil, QC, Canada) containing 750 µl absolute ethanol. Preliminary experiments indicated that mycolactone is stably preserved in ethanol for at least 3 weeks. Tubes were wrapped and kept in the dark at room temperature. Samples were usually shipped overnight to the Harvard lab within 24 hours and on one occasion after 7 days for logistical reasons.
The EtOH solvent was transferred to a glass vial (VWR 66011-041) and evaporated. Footpad was weighed (wet weights of footpads varied from ∼50 mg (grade 1 infection) up to 120 mg (grade 4 infection)), before transferring the tissue to a 7-ml Dounce tissue grinder and homogenization in 1.0 mL ethyl acetate (EtOAc). The homogenate was filtered through a Pasteur pipette containing a cotton plug into the original glass vial that had contained the EtOH solvent. The pestle was then rinsed with ∼1.5 ml EtOAc and the solvent was again evaporated. After evaporation, 50 µl of EtOAc was added to the vial and 35 µl was spotted onto a 3×6 cm fluorescent-dye free TLC plate (TLC Silica gel 60, EMD Millipore, Darmstadt, Germany; Gibbstown, NJ, USA) along with spots for 5, 10, and 20 ng synthetic mycolactone A/B standards. The plates were developed in 90∶10∶1 chloroform∶methanol∶water, air-dried, and dipped in boronic acid , heated for 5∼10 seconds at 100°C, before wiping the glass back with acetone on a paper towel. The plate was placed on a UV lamp with a 365 nm filter. Fluorescent spot intensity was compared to that of the standards to estimate the amount of mycolactone A/B in the sample. TLC photos were taken and subjected to resolution enhancement (Adobe Photoshop CS 6). TLC-pictures thus obtained serve for recording purposes, although the sensitivity with eye-analysis is better. For illustration, F-TLC pictures for Week 8 of untreated and RS-treated (for 2 weeks) are shown in Figure 1.
TLC-photos were taken and subjected to resolution enhancement (Adobe Photoshop CS 6). Panel A: untreated mouse. By visual comparison with the controls, the amount of mycolactone A/B in the right hind footpad (RHFP) sample was estimated to be 35–40 ng, which corresponds to 50–57 ng per footpad. No mycolactone A/B was detected in the left hind footpad (LHFP). Panel B: RS-treated (for 2 weeks) mouse. By visual comparison with the controls, the amount of mycolactone A/B in the RHFP sample was estimated to be 15–20 ng, which corresponds to 21–28 ng per footpad. No mycolactone A/B was detected in the LHFP.
As 70% of the EtOAc solution (35 µl out of 50 µl EtOAc) was used for F-TLC analysis, an amount of mycolactone A/B present in a footpad corresponds to (estimated amount from F-TLC) ng×(50/35).
GraphPad Prism 4 was used to compare group means by student's T test and analysis of variance and linear regression analysis for comparison of slopes and intercepts
The most rapid but least specific method of assessing M. ulcerans infection in human disease is to check for typical lesions. In the mouse model where infection time is known, the method is straightforward and well documented , , , . Figure 2 shows a detailed assessment of swelling progression with weekly observations. Swelling was suggested as early as 4 weeks after infection with unambiguous enlargement (grade 1±0.25) of footpads at week 5. The average footpad-swelling grade increased to level 2 (2.25±0.66) at week 6 and increased again to grade 3 (3.17±0.38) at week 7. At week 8 when the average reached 3.5±0.00, mice were sacrificed per protocol. The contralateral uninfected footpads showed no indications of swelling throughout the experiment. What was unknown in this time course was whether swelling is preceded by the presence of detectable mycolactone or if the number of organisms present in the footpad determines swelling.
After infection in the right hind footpad (RHFP), grade 1 swelling was first detected at 5 weeks. Treatment began when swelling averaged grade 2 at week 6. Swelling continued to increase for the next two weeks to grade 3.5 in untreated control mice (red squares). Swelling was arrested in mice treated with either rifampin and streptomycin (RS, green circles) or rifampin and clarithromycin (RC, blue triangles) and then declined at a comparable rate to a grade of <1 over the 5-week treatment period used in this experiment. No swelling occurred in the uninfected contralateral left hind footpads.
In this experiment, footpads stored in absolute ethanol were shipped overnight to the chemistry lab and quantitative mycolactone A/B results were determined within 24–48 hours of footpad harvest. As shown in Figure 3, mycolactone was detectable at ∼11 ng (∼7.5 ng×50/35)/footpad at week 4, one week before the observation of unambiguous footpad swelling. The amount increased to 26±2 ng ((18±2 ng)×50/35)/footpad at week 5, 31±2 ng ((22±2 ng)×50/35) at week 6, the beginning of treatment, 40±2 ng ((28±3 ng)×50/35) at week 7, and 49±4 ng ((34±3 ng)×50/35) at week 8 in untreated mice. These results indicate that the mycolactone toxin is present in “pre-clinical” lesions and can be detected in footpad tissue extracts by fluorescent TLC.
After infection with M. ulcerans in the right hind footpad (RHFP), ∼11 ng (∼7.5 ng×50/35) mycolactone A/B per footpad was detected at 4 weeks, one week before the observation of grade 1 swelling of the footpads. Treatment began when swelling averaged grade 2 at week 6 and mycolactone A/B levels were at 31±2 ng ((22±2 ng)×50/35) per footpad. Mycolactone production continued to increase for the next two weeks in untreated control mice (red squares), reaching 49±4 ng ((34±3) ng×50/35). Mycolactone production was arrested in mice treated with either rifampin and streptomycin (RS, green circles) or rifampin and clarithromycin (RC, blue triangles) and then declined to near undetectable levels (<5 ng) over the 5-week treatment period used in this experiment. At no time was mycolactone A/B detected in the contralateral left hind footpads.
M. ulcerans multiplication
Using quantitative culture at 32°C on selective Middlebrook 7H11 plates, countable colonies were present only after 10 weeks. At baseline, on day 1 after infection the CFU counts were 3.45±0.34 log10 per footpad. There was a gradual increase weekly with the CFU burden being 3.65±0.17, 4.26±0.18, 4.50±0.26, 4.92±0.19, and, at the time of detectable footpad swelling, just over 5 log10 at 5.20±0.10 log10 per footpad at weeks 1, 2, 3, 4, and 5, respectively, after infection (Figure 4). After initial footpad swelling, there was a further increase in M. ulcerans CFU to 5.96±0.26 log10 at which point there was a plateau with counts at subsequent weeks (7 and 8) being 6.13±0.28 and 6.23±0.41 log10/footpad, respectively. However, swelling and mycolactone production continued to increase. From these data, we conclude that footpad swelling only occurs after there are approximately 5log10 organisms in the footpad and that bacterial multiplication increases only slightly after that time while footpad swelling increases dramatically.
After infection in the right hind footpad (RHFP), there were increases in the numbers of M. ulcerans detected in the footpads. At week 4, the time of detectable mycolactone A/B, there were 4.9±0.2 log10 CFU in the footpads and there were 5.2±0.1 log10 CFU at week 5, the time of observable footpad swelling. CFU levels peaked at 6.2±0.4 log10, at week 8 in untreated mice, little changed from the 6.0±0.3 log10 found at the beginning of treatment at week 6. M. ulcerans growth was arrested in mice treated with either rifampin and streptomycin (RS, green circles) or rifampin and clarithromycin (RC, blue triangles). After 5 weeks of RS treatment, all footpads were culture negative whereas 3/5 mice treated with RC were culture negative.
Impact of RIF+STR and RIF+CLR treatment
On average, footpad swelling decreased steadily after the onset of treatment (week 6) with either the current standard regimen of RIF+STR or the proposed oral regimen of RIF+CLR from an average of grade 2 to an average of less than grade 1 as shown in Figure 2. Treatment was for only 5 weeks rather than the standard 8 weeks, which we have shown previously  using RIF+STR to render all or nearly all mice free of detectable footpad swelling. From these data, it would appear that the RIF+CLR combination should be equally effective as the RIF+STR combination in eliminating apparent signs of disease.
Over the 5 weeks of treatment, there was also a steady decrease in the production of detectable mycolactone A/B by F-TLC, regardless of antimicrobial regimen. This suggests that the drugs cripple mycolactone production either by inhibiting the machinery of the M. ulcerans plasmid or by killing the organism. Levels declined from 29±2 ng/footpad at the beginning of treatment to less than 5 ng/footpad after 5 weeks of treatment at week 11. Again, neither regimen displayed discernible superiority on disabling the production of mycolactone A/B (Figure 3).
M. ulcerans multiplication and survival.
As shown previously , , there is a rapid decrease in the number of M. ulcerans CFU after the beginning of treatment with RIF+STR. The decrease in this experiment was greater during the second week of treatment than during the first week, particularly in the RIF+STR-treated mice and these mice were all culture negative by the completion of 5 weeks of treatment (Figure 4). There was a parallel decrease in the RIF+CLR-treated mice in which 3 of 5 mice were culture negative by the completion of treatment. In summary, although there was no significant difference between the slopes of the curves of the two regimens as assessed by linear regression analysis, the time to culture negativity at 10.5 weeks vs. 11.1 weeks was statistically significantly earlier (p<0.025) in mice treated with RIF+STR.
The described developments in the fluorescent TLC procedure for the detection of mycolactone A/B in mice infected with M. ulcerans may have practical implications. This detection technique for the unique toxin of M. ulcerans may enable simpler and earlier specific diagnosis of Buruli ulcer in humans. Acid-fast microscopy for detection of M. ulcerans is also relatively rapid but lacks both sensitivity and specificity and histology requires expertise often not present in endemic areas. Molecular tests can also be applied but have similar limitations though PCR is relatively sensitive , . The most sensitive and specific method of detection is culture at 32°C on microbiological media but it requires up to 8 weeks for detection and up to 12 weeks for quantification in this model , ,  and is prone to contamination. Here, detection of mycolactone, a specific marker of M. ulcerans, was achieved within days of tissue harvest and even before the presence of a lesion (i.e., footpad swelling) in the mouse model. Compared to our previous studies  with frozen footpads and mycolactone detection by mass spectrometry, storage in absolute ethanol appears to be the key for detection at earlier phases of the infection and to increase sensitivity of TLC. Ethanol is also a more practical option than deep-freezing in the field. Experiments comparing ethanol with iso-propanol and ethyl acetate as the storage medium indicated that iso-propanol might be slightly superior to ethanol but that ethanol is clearly superior to ethyl acetate (unpublished observations). The differences were principally in the degree of diffusion of the spots. In footpads not kept in any of these solvents, there was almost complete elimination of detectable mycolactone.
We have also more precisely determined the relationship between footpad swelling, toxin production, and bacterial multiplication. Mycolactone A/B can be detected before the onset of footpad swelling when there are <105 bacilli per footpad and swelling occurs when there are >105 bacilli in the footpad. As observed previously , there is a plateau in bacillary numbers soon after the onset of swelling, even though swelling continues to increase. Unlike the CFU counts, toxin concentrations continue to increase as swelling increases. It remains to be determined how this dynamic interaction occurs in human lesions, which are not at all as circumscribed as those in the mouse. In humans, it will also be important to determine the best sites within lesions and the best techniques (e.g., swab or fine needle aspirate) to obtain toxin-containing specimens.
The impact of drug treatment with RIF-STR on footpad swelling and cultivable M. ulcerans was confirmed in these experiments. Importantly, we also observed a reduction in detectable mycolactone after the onset of drug treatment. In all three cases, the observations were made on a weekly basis providing further precision to the observations. We also found that the all-oral alternative RIF+CLR regimen for Buruli ulcer treatment, though possibly less bactericidal, appears to be equally active as the standard RIF+STR regimen in reducing swelling and blocking toxin production. Thus, the inhibition of the enzymatic machinery involved in producing a virulence factor may be as effective as and possibly less toxic than the killing of the bacteria.
The fluorescent TLC method could be an excellent tool for both the rapid and early detection of M. ulcerans infection and for monitoring the response to antimicrobial chemotherapy. The assay is practical in that absolute ethanol is readily available in all clinics and mycolactone is preserved in absolute EtOH at room temperature for at least 3 weeks (data not shown). The assay should be practical in intermediate level laboratories, thus facilitating confirmation of diagnoses before the onset of ulceration or soon after the onset of treatment.
Schematic of fluorescent thin layer chromatography (f-TLC) procedure with examples. Top left) Explanation of the f-TLC method; Top right) Schematic of f-TLC layout. Center, Stained TLC plates of mouse footpads, untreated on left and treated (RS) on right, from top to bottom: 6, 7, and 8 weeks after infection.
Conceived and designed the experiments: PJC JHG. Performed the experiments: PJC YX ST SYL. Analyzed the data: PJC JHG DVA ELN YK YX. Contributed reagents/materials/analysis tools: YK YX KHK PJC ELN JHG. Wrote the paper: PJC JHG ELN YK.
- 1. Converse PJ, Nuermberger EL, Almeida DV, Grosset JH (2011) Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? Future Microbiology 6: 1185–1198. doi: 10.2217/fmb.11.101
- 2. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283: 854–857. doi: 10.1126/science.283.5403.854
- 3. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, et al. (2004) Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A 101: 1345–1349. doi: 10.1073/pnas.0305877101
- 4. Fenner F (1956) The pathogenic behavior of Mycobacterium ulcerans and Mycobacterium balnei in the mouse and the developing chick embryo. Am Rev Tuberc 73: 650–673.
- 5. Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, et al. (2001) Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 45: 3109–3112. doi: 10.1128/aac.45.11.3109-3112.2001
- 6. Dega H, Bentoucha A, Robert J, Jarlier V, Grosset J (2002) Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 46: 3193–3196. doi: 10.1128/aac.46.10.3193-3196.2002
- 7. Dega H, Robert J, Bonnafous P, Jarlier V, Grosset J (2000) Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 44: 2367–2372. doi: 10.1128/aac.44.9.2367-2372.2000
- 8. Chauty A, Ardant M-F, Adeye A, Euverte H, Guedenon A, et al. (2007) Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli Ulcer (Mycobacterium ulcerans Disease). Antimicrob Agents Chemother 51: 4029–4035. doi: 10.1128/aac.00175-07
- 9. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, et al. (2005) Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans. Antimicrob Agents Chemother 49: 3182–3186. doi: 10.1128/aac.49.8.3182-3186.2005
- 10. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, et al. (2010) Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. The Lancet 375: 664–672. doi: 10.1016/s0140-6736(09)61962-0
- 11. Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, et al. (2010) Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 54: 3678–3685. doi: 10.1128/aac.00299-10
- 12. George KM, Pascopella L, Welty DM, Small PL (2000) A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 68: 877–883. doi: 10.1128/iai.68.2.877-883.2000
- 13. Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T (2008) Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep 25: 447–454. doi: 10.1039/b803101k
- 14. Hong H, Gates PJ, Staunton J, Stinear T, Cole ST, et al. (2003) Identification using LC-MSn of co-metabolites in the biosynthesis of the polyketide toxin mycolactone by a clinical isolate of Mycobacterium ulcerans. Chem Commun (Camb) 2822–2823. doi: 10.1039/b308163j
- 15. Hong H, Spencer JB, Porter JL, Leadlay PF, Stinear T (2005) A novel mycolactone from a clinical isolate of Mycobacterium ulcerans provides evidence for additional toxin heterogeneity as a result of specific changes in the modular polyketide synthase. Chembiochem 6: 643–648. doi: 10.1002/cbic.200400339
- 16. Kishi Y (2011) Chemistry of mycolactones, the causative toxins of Buruli ulcer. Proc Natl Acad Sci U S A 108: 6703–6708. doi: 10.1073/pnas.1015252108
- 17. Spangenberg T, Kishi Y (2010) Highly sensitive, operationally simple, cost/time effective detection of the mycolactones from the human pathogen Mycobacterium ulcerans. Chemical Communications 46: 1410–1412. doi: 10.1039/b924896j
- 18. Demangel C, Stinear TP, Cole ST (2009) Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol 7: 50–60. doi: 10.1038/nrmicro2077
- 19. Song F, Fidanze S, Benowitz AB, Kishi Y (2002) Total synthesis of the mycolactones. Org Lett 4: 647–650. doi: 10.1021/ol0172828
- 20. Song F, Fidanze S, Benowitz AB, Kishi Y (2007) Total Synthesis of Mycolactones A and B. Tetrahedron 63: 5739–5753. doi: 10.1016/j.tet.2007.02.057
- 21. Martins TG, Gama JB, Fraga AG, Saraiva M, Silva MT, et al. (2012) Local and Regional Re-Establishment of Cellular Immunity during Curative Antibiotherapy of Murine Mycobacterium ulcerans Infection. PLoS ONE 7: e32740. doi: 10.1371/journal.pone.0032740
- 22. Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, et al. (2005) Infection with Mycobacterium ulcerans Induces Persistent Inflammatory Responses in Mice. Infect Immun 73: 6299–6310. doi: 10.1128/iai.73.10.6299-6310.2005
- 23. Ruf MT, Schutte D, Chauffour A, Jarlier V, Ji B, et al. (2012) Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model. Antimicrob Agents Chemother 56: 687–696. doi: 10.1128/aac.05543-11
- 24. Sarfo FS, Converse PJ, Almeida DV, Zhang J, Robinson C, et al. (2013) Microbiological, Histological, Immunological, and Toxin Response to Antibiotic Treatment in the Mouse Model of Mycobacterium ulcerans Disease. PLoS Negl Trop Dis 7: e2101. doi: 10.1371/journal.pntd.0002101
- 25. Torrado E, Adusumilli S, Fraga AG, Small PLC, Castro AG, et al. (2007) Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 75: 3979–3988. doi: 10.1128/iai.00290-07
- 26. Torrado E, Fraga AG, Castro AG, Stragier P, Meyers WM, et al. (2007) Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun 75: 977–987. doi: 10.1128/iai.00889-06
- 27. Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, et al. (2011) Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice. PLoS Negl Trop Dis 5: e933. doi: 10.1371/journal.pntd.0000933
- 28. Chauty A, Ardant M-Fß, Marsollier L, Pluschke G, Landier J, et al. (2011) Oral Treatment for Mycobacterium ulcerans Infection: Results From a Pilot Study in Benin. Clinical Infectious Diseases 52: 94–96. doi: 10.1093/cid/ciq072
- 29. Ji B, Chauffour A, Robert J, Jarlier V (2008) Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 52: 1912–1916. doi: 10.1128/aac.00193-08
- 30. Pettit JHS, Marchette NJ, Rees RJW (1966) Mycobacterium ulcerans infection. Clinical and bacteriological study of the first cases recognized in South East Asia. British Journal of Dermatology 78: 187–197. doi: 10.1111/j.1365-2133.1966.tb12204.x
- 31. Converse PJ, Almeida DV, Nuermberger EL, Grosset JH (2011) BCG-Mediated Protection against Mycobacterium ulcerans Infection in the Mouse. PLoS Neglected Tropical Diseases 5: e985. doi: 10.1371/journal.pntd.0000985
- 32. Zhang T, Li S-Y, Converse PJ, Almeida DV, Grosset JH, et al. (2011) Using Bioluminescence To Monitor Treatment Response in Real Time in Mice with Mycobacterium ulcerans Infection. Antimicrob Agents Chemother 55: 56–61. doi: 10.1128/aac.01260-10
- 33. Beissner M, Herbinger KH, Bretzel G (2010) Laboratory diagnosis of Buruli ulcer disease. Future Microbiol 5: 363–370. doi: 10.2217/fmb.10.3
- 34. Beissner M, Symank D, Phillips RO, Amoako YA, Awua-Boateng N-Y, et al. (2012) Detection of Viable Mycobacterium ulcerans in Clinical Samples by a Novel Combined 16S rRNA Reverse Transcriptase/IS2404 Real-Time qPCR Assay. PLoS Negl Trop Dis 6: e1756. doi: 10.1371/journal.pntd.0001756
- 35. Almeida DV, Converse PJ, Li SY, Tyagi S, Nuermberger EL, et al. (2013) Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis 7: e2085. doi: 10.1371/journal.pntd.0002085